.png){kind=icon}
.png){kind=icon}
Return
Anoikis resistance as a key driver of glioma malignancy: From ECM detachment to potential druggable targets
.png){kind=icon}
PRE
AI
Y
C
X
Y
Q
DOI：10.1016/j.bbcan.2026.189608.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
• Gliomas, especially glioblastoma, exhibit marked invasiveness, recurrence, and therapeutic resistance. • Detachment or dysregulated adhesion to the extracellular matrix (ECM) triggers anoikis, a specialized apoptotic process in mammalian cells. • Anoikis resistance is cooperatively mediated by dysregulated survival-related regulators, autocrine/paracrine signaling, protective autophagy, epithelial-mesenchymal transition (EMT), and metabolic reprogramming. • Anoikis resistance fuels glioma stemness, local infiltration, recurrence, and even metastatic dissemination. • Preclinical evidence indicates that pharmacological inhibition of specific mediators of anoikis resistance can restore anoikis sensitivity in glioma cells, presenting a promising therapeutic strategy.
Keywords:
Anoikis resistance
Glioma malignancy
Extracellular matrix
Glioma stemness
Therapeutic targets
Journal
B
IF:
0
Papers:
105
Citations:
0
Organization
Cited Papers